UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines Anne MonksErik D. HarrisEdward A. Sausville OriginalPaper Pages: 95 - 107
Proteasome Inhibition: a New Strategy in Cancer Treatment Julian AdamsVito J. PalombellaPeter J. Elliott OriginalPaper Pages: 109 - 121
DNA G-Quadruplexes, Telomere-Specific Proteins and Telomere-Associated Enzymes as Potential Targets for New Anticancer Drugs Eric RaymondJean-Charles SoriaDaniel D. Von Hoff OriginalPaper Pages: 123 - 137
Cytotoxic Effects of Topotecan Combined with Various Active G2/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines Miquel TaronCarmen PlasenciaMónica Guillot OriginalPaper Pages: 139 - 148
Chemotherapy in Non-Small Cell Lung Cancer Christopher J. SweeneyAlan B. Sandler OriginalPaper Pages: 157 - 186
CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer Christopher W. RyanKeith L. ShulmanNicholas J. Vogelzang OriginalPaper Pages: 187 - 191
A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma Eric J. SmallRobert FiglinChris Bowden OriginalPaper Pages: 193 - 198
A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339) John S. MacdonaldJoth L. JacobsonMarcel Conrad OriginalPaper Pages: 199 - 202